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Summary
Highly purified CD1-3-4'8- human thymocytes were obtained by panning techniques
combined withcelldepletionwithantibody-coatedmagneticbeads. Most ofthesecells expressed
cytoplasmic CD3 antigen, as assessed by mAbs known to react with the CD3E chain. After
culture with low doses ofPMA (0.5 ng/ml) and subsequent addition (at 24 h) ofrecombinant
interleukin 2 (rIIr2; 100 U/ml) cells underwent extensive proliferation (40-60-fold ofthe initial
cell input after 2 wk). The majority ofthe proliferating cells wereCD3-TCR-. Theremaining
cells (5-40%) were represented by CD3+TCR y/6+ (BB3-A13+) cells. Further removal of
CD3+TCR-y/8+ cells resulted in highly purified CD3- populations that further proliferated
in culture with no substantial phenotypic changes. When CD3+ thymocytes were cultured
under the same experimental conditions, only CD3+ TCRa/ß+ cells could be detected, thus
indicating that PMA didnot agect thesurface expression ofthe CD3/TCR complex, but rather
induced preferential growth of CD3- thymocytes. Surface marker analysis of cultured CD3-
thymocytes showed that they were homogeneously CD7+, whereas low proportions of cells
expressedCD2and CD8 antigens. Amongthenaturalkiller (NK) cellmarkers, CD56washighly
expressedby all cells, whereas CD16, CD57, CD11b, NKH2, andGL183wereabsent. Importantly,
these cells were different from peripheral NK cells, as 80-95% ofthem expressed cytoplasmic
CD3 antigen. Functional analysis revealed a strong cytolytic activity against both NK-sensitive
(K562) and NK-resistant (M14, Daudi) human target cells. In a redirected killing assay against
the FcyR+ P815 cells, mAbs specific for triggering molecules including CD3, CD2, and CD16
failed to augment target cell lysis, whileastrong cytolytic effect wasinducedbyPHA. Inaddition,
PHA alone or in combinationwithPMAinducedtumornecrosis factor a(TNF-a)and interferon
y (IFN-y) (but not 11,2) production by CD3- thymocytes. Cloning of fresh CD1-3-4-8-
thymocytes in the presence of PMA and rIIr2 resulted in CD3-CD56+ clones that displayed
a pattern of cytolytic activity and lymphokine production similar to that of the polyclonal
populations. Northern blot analysis oftranscripts coding for CD3/TCRmolecules revealed the
presence ofCD3r, e, and y transcripts, while CD3E was undetectable. Mature transcripts for
both y and 6 TCR chains couldbe detected, whereas no TCR-a mRNA and only a truncated
(1.0 kb) form of TCRß mRNA were revealed. These data suggest that CD3- cultured thy-
mocytes may be, at least in part, representative of a T cell maturation stage that precedes the
surface expression of the CD3/TCR molecular complex. Southern blot analysis of the TCR-6
gene rearrangements revealed that the cultured CD3- thymocytes retained a germline
configuration.
T
cell development within the thymus is characterizedby
theprogressiveacquisitionoffunctionallyrelevant and/or
lineage-specific molecules (1-14). Three major, phenotypi-
cally defined subsets havebeen identified on the basis of the
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expression ofthe CD1, CD4, CD8, andCD3/TCRdifferen-
tiation antigens. A small (1%) CD1-3-4-8- subset that
expresses CD7and CD2antigens is generally thought toin-
cludethemostimmaturethymocytes(1, 4, 6). Asecond subset,
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cells that coexpress the CD4and CD8antigens (1, 4, 6, 15).
The third subset is represented by "mature" surface CD3/
TCR+ thymocytes that express either CD4 or CD8 an-
tigens (1, 4, 6).
In humans, the small subset characterized by the
CD1-3-4-8- surface phenotype (and by the presence of cy-
toplasmic CD3E chain) hasbeen extensively studied in vitro
in orderto analyzeits abilityto undergo phenotypic and func-
tional maturation (16-22).Thesestudies have suggestedthat
CD1-3-4-8- thymocytes, under appropriate culture con-
ditions (20, 21), undergo differentiation and give rise to the
two major subsets of peripheral T lymphocytes expressing
either TCR-a//3 or -y/& However, a precise analysis of the
sequential stages occurring during T cell maturation (from
CD1-3'4-8- towards CD3+TCR+ cells) has been ham-
pered primarily by the limited number of C131 -3-4-8-
cells available after thymocyte fractionation. In addition, it
hasbeen reported that after culture thesecells rapidly acquire
surface CD3/TCR (17, 18).
In the present study we have defined culture conditions
that allow extensiveproliferation of CD3- thymocyte popu-
lations and clones without maturation into surface CD3+
TCR+ cells. These cells expressed cytoplasmic CD3E chain
andacquired surface CD56 antigen, although they lacked other
NK cell markers. They expressedeffector functions including
cytolytic activity and lymphokine production. Analysis of
mRNA for CD3 or TCR chains revealed the presence of full-
length transcripts forboth TCR-y and -6 chains and the ex-
pression of transcripts for C]33f, E and ybut not for CD3E
chain. Analysis of the TCR6 gene rearrangements revealed
a germline configuration.
Materials and Methods
Antibodies andReagents.
￿
mAbs Leu4 (anti-CD3), Leu2a (anti-
CD8), Leu3a (anti-CD4), Leu9 (anti-CD7), Leu5b(anti-CD2), Leul
(anti-CD5), TCRA (antiWT31), Leu19(anti-CD56), LeuM5(anti-
CD11b), Leu7 (anti-CD57), Leullc (anti-CD16), anti-HPCA-1
(anti-CD34), anti-11,2 receptor (anti-CD25), and anti-HLA class
II were purchased from Becton Dickinson (MountainView, CA).
OKT6 (anti-CDI) andOKT3a(anti-CD3) mAbs were from Ortho
Immune Diagnostic (Raritan, NJ).Anti-TCRS1 waspurchasedfrom
T Cell Sciences Inc. (Cambridge, MA). Anti-HLA class I mAb
(W6/32)was from Dakopatts (Glostrup, Denmark). CK248(anti-
CD28) (23), CD2-1 (anti-T11-2) (24), CD2-9 (anti-T11-1) (24),
Mar206 (anti-T11-1) (25), VD4(anti-CD16) (26), KDl (anti-CD16)
(26), A13(antiVdelta-1) (27, 28), BB3(antiVdelta-2) (28, 29), JT3A
(anti-CD3) (30),J90(anti-CD11a) (30), andGL183 (31) mAbs were
obtained in ourlaboratory. FITC-conjugated goat anti-mouse IgG
waspurchasedfrom Cappel Laboratories (Cochranville, PA). NKH2
and UCHT1 mAbs were generous gift of Drs. T Hercend (In-
stitut GustaveRoussy, Villejuif, France)andP C. L. Beverley (Im-
perial Cancer Research Fund Human Tumour Immunology Group,
London, UK), respectively. PMA was from Sigma Chemical Co.
(St. Louis, MO). PBS, PHA, RPMI 1640 medium, FCS, L-glu-
tamine, penicillin-streptomycin were purchasedfrom GibcoLabora-
tories (Grand Island, NY). rIL2 was kindly provided by Cetus
Corp. (Emeryville, CA).
Isolation ofCD1 -3-4 -8 - Thymocytes.
￿
Normal human thymo-
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cyteswere obtained from thymus fragmentsremovedduring cardiac
surgeryofpatients 2mo to 4yr oldas described(21). Theisolation
of CDi-3-4-8- thymocytes (<I% of total thymus cell suspen-
sions) were obtained after negative depletion by panning using
saturating amounts of anti-CD1 (OKT6), anti-CD3 (Leu4), anti-
CD4 (Leu3a), and anti-CD8 (Leu2a) mAbs (21). After panning,
the contamination with "positive" cells was 10-25% (as assessed
by immunofluorescence). Cell suspensions were further depleted
of "positive" cellsby usingmagnetic beadscoated with anti-mouse
IgG (Oxoid Italiana S.p.A., Milan) as described (32). Both cell
purification steps were performed at 4°C. After this second step,
cells recovered were >99.9% CDi-3`4-8-. These highly purified
thymocyte suspensions were used in further experiments.
Generation ofCD3 - Cell Linesfrom CD1-3-4 -8- Thymocytes.
Highly purified CD1-3-4-8- thymocytes were cultured in 200
Al of RPMI 1640 medium supplemented with 10% ofFCS (Gibco
Laboratories) in 96 U-bottomed microplates (Greiner, Nurtingen,
FRG) either in thepresence or in theabsenceof0.5 ng/ml ofPMA
(Sigma Chemical Co.) or with 0.5 NAg/ml of PHA(Gibco)for24 h.
Afterthis period,100pl ofculturemedium wasdiscardedand100 p1
of rIL2-containing (100 U/ml) (Cetus Corp.) medium (with no
PHAor PMA) was added. Within 2-5 devident cell growth could
be observed. Cultures were repeatedly splitted by adding 100 JAI
of the same IL2-containing medium. Surface marker analysis of
stimulated CD1-3-4-8- thymocytes was performed at different
time intervals. After 10-15 dofculture, high proportions (60-95%)
of CD3- proliferating cells could be detected in cultures pulsed
with PMA. These cultures were further depleted of CD3+ cells
by using antibody-coated magnetic beads. The resulting popula-
tions contained <0.1% CD3+ cells. These highly purified CD3-
cells proliferated in culture for up to 8 wk and maintained their
CD3- phenotype.
Flow Cytometry Analysis.
￿
The techniques used have been de-
scribed in detail elsewhere (23) . Briefly, aliquots of 105 cells were
stained with thecorresponding mAbfollowed by FITC-conjugated
goat anti-mouse Ig (Cappel Laboratories). Control aliquots were
stained with an unrelated mAb (Becton Dickinson). The samples
were analyzed on a flow cytometer (FACStar, Becton Dickinson)
gated to exclude no viable cells. The presence ofcytoplasmic CD3
antigen into CD3- proliferating thymocytes was performed as
follows: 105cells were fixed in formaldehyde (Sigma Chemical Co.)
(3.7% in PBS) for 5 minat room temperature (RT), washed twice,
andthen permeabilizedwith 0.01% (final concentration) of N-P40
(Sigma Chemical Co.) for 5 min at RT. Treated cells were exten-
sively washed in PBS (Gibco Laboratories) and then stained with
different anti-CD3 mAbs (Leu4, UCHT1, OKT3a) followed by
the FITC-conjugated goat anti-mouse Ig. Undertheseconditions,
no detectable change of the cell size (as assessed by forward scatter
and side scatter analysis) could be observed. In addition, no
modification of the pattern of reactivity with several mAbs could
be detected after cell treatment.
Cloning ofCDI -3-4-8- Thymocytes.
￿
Cloning of highly
purified CD1-3-4-8- thymocytes was performed under limiting
dilution conditions (33) in 96-well U-bottomed plates (Greiner)
in the presence of 105 irradiated PBMC as feeder cells and0.5 ng/ml
ofPMA(Sigma Chemical Co.), as previously described(33). After
24 h 100U/ml rIL2was addedto each well. IL2 supplementation
was repeated at 4-5-d intervals. Evident cell growth could be de-
tected after 12-18dof culture. Clones were maintained in culture
for up to 1 mo.
Functional Assays.
￿
Cytolytic activity of polyclonal or clonal
CD3- thymocytes was tested in a 4-h "Cr-release assay as previ-
ouslydescribedin detail (34). Briefly, NICsensitive (K562) or NK-resistant (Daudi, M14) tumorcell lines werelabeled with 100ACi/
106 cells of sodium chromate (34) and seeded into 96-well Vbot-
tomed plates (Greiner) at 5 x 10" cells/well. CD3- thymocytes
were used as effector cells at E/T ratios ranging from 25:1 to 6:1
in a final volume of 200 N .1 of RPMI 1640. After 4 h, 100 1A1 of
supernatant wasremovedfrom each well andcounted in agamma
counter (Gamma 5500; Beckman Instruments, Fullerton, CA) for
the assessment of "Cr release. The percent specific release was de-
termined as previously described (34). In a redirected killing assay,
the P815 (FcyR+) murine mastocytoma, used as target cells, were
seeded at an E/T ratio of 1:1. The cytolytic test was performed
in medium alone, or in the presence of 0.5 wg/ml of PHA or 20
P,1 of culture supernatant of various mAbs including MAR206,
CD2-9, VD4, andJT3A. To evaluate the production of TNF-a,
IFN-y, and IL2, CD3- thymocytes were stimulated for 36 h in
culture medium in either the presence or absence of PMA (0.5
ng/ml) and/or PHA(0.5 Wg/ml). Culture supernatants were tested
for TNF-cr,IFN-y, and IL2activity by enzyme immunoassays (T
Cell Sciences).
Southern andNorthern Blot Analysis.
￿
DNA was extracted from
the B cell leukemia line Raji and a CD3- proliferating thymocyte
population, then digested with the BamHI restriction enzyme.
DNA (5 hg)waselectrophoresed through 0.6% agarose andtrans-
ferred to Gene Screen Plus (New England Nuclear, Boston, MA)
filters described by Southern (35). Thetransferred DNAwas cova-
lently attached to an air-dried membraneby 1-min exposure to 1,200
juW/cm of UV light. The filter wasprehybridized, hybridized, and
washed as described (36). The probe used was the 1.5-kb EcoRI
fragment oftheTCR-6cDNA (37). RNAwasprepared, size frac-
tionated by electrophoresis in agarose gels containing formalde-
hyde, and subsequently blotted and hybridized as previously de-
scribed (36). Theprobes used were the following: a 1.1-kb EcoRI
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fragment of the TCR-a cDNA clone PY1.4 (38), a 0.77-kb Pstl
fragment of the TCR$ cDNA clone IUR-f3 2.(39), a 1.6-kb
EcoRI fragment ofthe TCRycDNA clone HGPO2 (40), a 1.5-kb
EcoRI fragment of the TCR-6 cDNA (37), a 0.7-kb EcoRl iag-
ment oftheCD3y cDNA clone pJ6T3,y-2 (41), a0.9-kb OxaNI/
BamHI fragment CD3e cDNA clone pCD3H(42), a 0.8-kb Pstl
fragment ofCD36 cDNA, derived from clone 25 (kindlyprovided
by Dr. Tak WMak, Ontario Cancer Institute, Toronto, Ontario),
and two 30-mer oligonucleotides overlapping by 10 complemen-
tary bases corresponding to the CD3('cDNA (43) (GGCCTGC-
TGGATCCCAAACTCTGCTACCTGandATGAAGAGGATIICC-
ATCCAGCAGGTAGCAG). Probes were labeled as described
(36). Blots were exposed to x-ray films using intensifying screens
at -70°C.
Results
Isolation of CDI-3-4-8- Thymocytes.
￿
CD1-3 -4 -8 -
thymocyte populations were obtained by the combined use
of panning techniques andcell depletion with antibody-coated
magnetic beads. This double-step cell isolation yielded highly
purified CD1-3 -4 -8 - populations containing <0.1% con-
taminating cells. In different experiments, the cell yield was
0.2-0.6% of the starting unfractionated thymocyte cell sus-
pension. Purified CD1-3 -4-8- thymocyte populations
contained a high proportion of surface CD7+ cells and vari-
able proportions of CD2+ cells (50-60%). Virtually no
CD25+, CD16+, CD56+, and CD11b+ cells could be de-
tected (Fig. 1) . In agreement with previous reports, most of
the CD1-3 -4 -8 - thymic cells expressed intracytoplasmic
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Figure 1.
￿
Surface phenotype of
CD1-3-4-8- resting thymocytes.
CD1-3- 4 - 8 - thymocytes were
isolated from total thymocytes by
panning techniques combined with
cell depletion with antibody-coated
magnetic beads, as described in
Materials and Methods. Cells were
stained with the mAbs indicated,
followed by FITC-conjugated goat
anti-mouse IgG. In the upper left
quadrant (negative control) cells
were stained with an irrelevant
mAb. Samples were analyzed on a
FACStar andresults are expressed as
loggreen fluorescence intensity vs.
number ofcells. Data are represen-
tative of six independent experi-
ments.
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CD34CD3 antigen, as assessed by both fluorescence microscopy
and cytofluorometric analysis (following cell membrane per-
meabilization) (not shown). It shouldbe noted that the anti-
CD3 mAbs used are knownto specifically reactwith the CD3e
chain (44) .
In VitroExpansion ofCD1 - 3 - 4 '8 - Thymic Cells.
￿
Given
the high degree of purity of the CD1 - 3 - 4 - 8 - thymic
populations, we further attempted to define culture condi-
tions suitable for theirvitro expansion. To this aim, cellswere
stimulated in the presence of rIL2 (100 U/ml), or PMA (0.5
ng/ml) or PHA (1 Kg/ml) added at time 0. All the stimu-
lated thymocyte populations were then expanded using cul-
ture medium containing IL2 but not PHA or PMA. At
different culture intervals, cells were analyzed for theirprolifer-
ating ability as well as for their surface phenotype. A strong
proliferative response could be detected after 48-72 h in the
presence of either PHA or PMA plus rIL2. Three- fivefold
less proliferation was detected in the presence of rIL2 alone
(not shown). Consistently, at later culture intervals, max-
imal cell expansion was detectable in cultures stimulated with
PMA and rIL2. For example, as shown in Fig. 2, the cell
number recovered after 2 wk was N50-fold higher than the
initial cell input. On the other hand, cell recovery in cultures
containing rIL2 alone or rIL2 and PHA was consistently
lower. In some experiments, cells were continuously grown
in culture for up to 8 wk with no substantial decrease in
cell proliferation. It should be noted that due to the rate of
cell growth, the starting PHA or PMA concentrations were
100-1,000-fold diluted in culture medium.
The cell surface phenotype expressed by purified CD3 -
thymocyte populations cultured under the different condi-
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Figure 2.
￿
Cell recovery upon culture of CD1-3- 4 -8- thymocytes in
the presence ofdifferent stimuli. 105 Purified CD1-3- 4-8- thymocytes
were cultured in culture medium alone ("), or in the presence of PHA
(") (0.5 wg/ml) or PM (/) (0.5 ng/ml). In allinstances rIIs2 was added
after 24 h. Cell recovery was evaluated after different culture intervals.
Similar data were obtained in three other independent experiments.
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tions described was analyzed. In agreement with previous
reports, cells cultured in the presence of rIL2 alone or IL2
plus PHA largely resulted in CD3+WT31+ cells. No cells
expressing TCRy/S (as assessed by mAbs BB3, A13, and
TCRS-1) could be detected under these culture conditions.
On the other hand, culture of CD3 - thymocytes in the
presence of PMA and IL2 gave rise (after 2 wk of culture)
to cell populations containing 60-95% CD3 - cells (not
shown). Interestingly, the minor CD3+ cell fractions were
homogeneously composed of A13+BB3 - cells, thus
representing the TCR-y/S+ subset utilizing the V61 gene
segment (45). These data indicate that the type of triggering
signal provided to CD1-3- 4 - 8 - thymocyte populations ap-
pears to influence the cell surface phenotype resulting after
culture. More importantly, in the presence ofPMA and rIL2
it was possible to obtain an extensive proliferation of cells
that expressed the original CD3`TCR- surface phenotype.
The above data suggest that the combination of low doses
of PMA and 11,2 induced extensive CD3 - thymocyte
proliferation, without substantial phenotypic changes. Since
PMA has been reported to downregulate the surface expres-
sion of the CD3/TCR complex in mature T lymphocytes
(46), we investigated whether low doses ofPMA used in order
to induce thymocyte proliferation (0.5 ng/ml) couldalso have
a similar effect on CD3+ thymocytes. To this aim, unfrac-
tionated, CD3- and CD3+ thymocyte populations were
stimulated with PMA (0.5 ng/ml) and rIL2. An extensive
proliferation could be detected with all cell populations tested.
However, surface marker analysis performed at day 14 showed
that in cultures derived from the CD3+ thymocyte fraction,
virtually no CD3 - cells could be detected. In addition,
proliferating cells were mostly characterized by the CD3+
WT31+ surface phenotype. Interestingly, large proportions
of CD3 - cells could be derived not only from purified
CD3 - thymocytes, but also from unfractionated popula-
tions. In the latter case, CD3+ cells represented 20-40% of
recovered cells and were composed of both TCRci/a+
(5-20%) and TCRy/S+ cells (10-25%) (not shown). Taken
together, these data indicate that the combined use of PMA
and rIL2 induces preferential growth of CD3 - thymocytes
without affecting the surface expression of CD3/TCR com-
plex in CD3+ thymocytes.
Phenotypic Analysis of Cultured CD3 - Thymocytes.
￿
CD3 -
thymocytes obtained by in vitro culture with PMA and rIL2
were further analyzed for their phenotypic and functional
properties, after further depletion of CD3+ cells. The
resulting populations contained <0.1% CD3 + cells. Anal-
ysis of surface antigens (Fig. 3) revealed that cells were
homogeneously CD7+, whereas variable (usually low) pro-
portions of cells expressed CD2 antigen. The expression of
CD2 antigen was detected by the use of several mAbs recog-
nizing different epitopes of the CD2 molecule (T11-1, T11-
2). Cells also lacked surface expression of CD1, CD4, CD28
(Fig. 3), CD5, TCRy/S, and TCRa//3 molecules (not
shown), while a minor proportion (<10%) expressed CD8
antigen (Fig. 3). Because the thymocyte populations exam-
ined, similar to peripheral CD3' NK cells, lacked surface
CD3/TCR complex, we analyzed a number ofsurface markersrn
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expressed by NK cells. Cells were homogeneously stained
by anti-CD56 mAb, but they did not express CD16, CD57
(Leu7), CD11b, NKH2, and GL183 surface antigens (Fig.
3) . In addition, differentfrom peripheral bloodNK cells, the
majority (80-95%) of cultured CD3- thymocytes were
found to express cytoplasmic CD3 antigen (Fig. 4).
Functional Analysis of Cultured CD3- Tltymocytes.
￿
We
next analyzed whether cultured CD3- thymocytes expressed
effector cell functions such as cytolyticactivity andlymphokine
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Figure 3.
￿
Surface phenotype of
cultured CD3- thymocytes. Cells
were stained with the indicated
mAbs followedby FITC-conjugated
goat anti-mouse IgG. The upper
left quadrant (negative control)
represents cells stained with an ir-
relevant mAb. Samples were ana-
lyzed on a FACStar and results are
expressed as loggreenfluorescence
intensity vs. the number of cells.
Data are representative of four in-
dependent experiments.
production. In conventional "Cr-release assays, these cells
displayed a strong cytolytic activity against NK-sensitive
(K562) and NK-resistant (M14, Daudi) human target cells
(shown in Table 1). We also analyzed the ability ofthesecells
to lyse murine mastocytomaP815 cells in aredirected killing
assay using PHA or mAbs specific for "triggering" cell sur-
face molecules, including CD3, CD2, and CD16. As shown
in Table 2, while addition of PHA significantly augmented
target cell lysis, none of the stimulatory mAbs had anyeffect.
Figure 4.
￿
Cultured CD3- thy-
mocytes express cytoplasmic CD3
antigen. Cultured CD3- thymo-
cytes (A-C) were analyzed for cy-
toplasmic CD3 in comparison to
cultured CD3-CD16* peripheral
blood-derived populations (D-F).
Cells were stained with Leu4 (A,
D), UCHT1 (B, E), or OKT3a
(C,) mAbs and analyzed at the
FRCS aftercell fixation and mem-
branepermeabilization as described
in Materials and Methods. Dotted
lines represent cellsstainedwith an
unrelated mAb followed by the
FITC-conjugated reagent. Data are
representative ofsixindependent ex-
periments.
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NKH2 GL183These results are in line with the data of cytofluorometric
analysis showing lack of surface expression ofCD3 and CD16
molecules and low levels of CD2. These results also indicate
that PHA could induce CD3 - thymocyte triggering upon
interaction with surface molecules different from CD3, CD2,
and CD16.
Analysis of lymphokine production in response to either
PHA or PHA and PMA revealed that cultured CD3 -
thymocytes produced both IFN-y and TNF-a (Table 3), but
not IIr2 (not shown). As opposed to peripheral CD3 - NK
cells, the addition of exogenous rlIr2 did not significantly
increase the release of IFN-y and TNF-a (not shown).
Clonal Analysis ofCDI -3-4-8- Thymocytes.
￿
Since cul-
ture of CD1 -3 -4'8 - thymocytes in the presence of PMA
and rlL2 induced maximal cell proliferation in bulk culture,
we investigated whether the same requirements could be ap-
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Polyclonal populations andclones were homogeneously CD3-TCR-, expressed CD7 and CD56, but lacked CD16 andCD57 surface antigens.
i Results are expressed as percent of specific s1Cr release.
propriate also for inducing clonal growth under limiting di-
lution (33). The clonal efficiencies obtained were 1-3% in
four different experiments. Phenotypic analysis of clones
showed that the majority were CD3 -TCR -CD56+ .
Clones were analyzed for their cytolytic activity and lym-
phokine production. They were found to express acytolytic
pattern similar to that of bulk CD3- thymocyte populations
(see representative CD3 clones in Tables 1 and 2). All
CD3 - thymocyte clones analyzed produced both IFN-y and
TNF-a, but not IL2. The IFN-y and TNF-a production
by two representative clones are shown in Table 3.
Analysis of Transcripts Codingfor 'PCR and CD3 Chains in
CD3- Cultured Thymocytes. The availability of relatively
large numbers of proliferating CD3- thymocytes prompted
us to analyze the expression in thesecells oftranscripts coding
for either CD3y, 6, E, and ~ chains or TCR-a, -a, -'y, and
Table 2.
￿
Effect of PHA or mAbs Specific for Triggering Molecules on the Cytolytic Activity of Polyclonal or Clonal
CD3' Thymocytes Against P81S Target Cells
Thl and Th2 are representative CD3- thymocyte populations cultured in vitro for 4 wk. Th clones 1 and 2 are two representative
CD3-TCR-CD56 + clones derivedfrom highly purified CD1-3-4-8- thymocytes. Clones AP25.1 andRS12.5 are two representative PB-derived
clones expressing the CD3+TCR-a//3+CD8+ or the CD3-CD16+ surface phenotype, respectively.
t Results are expressed as percent specific s1Cr release at an E/T ratio of 1:1. MAR206 (anti-T11-1), CD2-9 (anti-T11-1), JT3A (anti-CD3), and
VD4 (anti-CD16) mAbs were used at the final concentration of 20 ng/ml.
Effector cell None PHA
Stimuli
MAR206
added to the
CD2-9
cytolytic test
MAR206 +
CD2-9 JT3A VD4
Thl' 5t 55 4 3 3 1 2
Th2 4 65 2 1 2 2 1
Clone Thl 3 70 1 0 2 2 0
Clone Th2 4 35 3 4 3 2 3
Clone AP25 .1 6 90 4 5 62 85 3
Clone RS12 .5 4 85 47 50 75 2 100
Table 1. Cytolytic Activity of Polyclonal or Clonal CD3- Thymocytes against NK-sensitive or NK-resistant Tumor Target Cells
Target cell
K562 at E/T M14 at E/T Daudi E/T
ratio of: ratio of: ratio of:
CD3-TCR-
thymocytes 25:1 12:1 6:1 25:1 12 :1 6:1 25:1 12:1 6:1
Polyclonal population 1" loot 85 70 85 70 55 90 70 60
Polyclonal population 2 95 80 65 75 60 45 81 65 50
Clone Thl 70 55 40 75 60 55 75 55 50
Clone Th2 100 75 50 90 70 53 95 70 42Table 3.
￿
TNF-a and IFN-y Production by Polyclonal or Clonal CD3- Thymocytes
105 thymocytecultures or clones (CD3 -CD56+) were cultured in triplicate microwells (final volume 200 Al/well) for 36 h at 37*C in the presence
of one or another of the stimuli indicated. PHA was used at 0.5 p,g/ml and PMAat 0.5 ng/ml as a final dilution. Supernatant fluids were collected
and tested for TNF-a and IFN-'Y content using an enzyme immunoassay as described in Materials and Methods.
t TNF-a is expressed as pg/ml.
S IFN-.y is expressed as U/ml.
-6 chains. As assessed by Northern blot analysis, in CD3 -
cultured thymocytes the levels of the transcripts for CD3e
and ~ chains were comparable to those of Jurkat or Peer T
cell lines used as positive controls. More importantly, the
CD3y transcript, known to be absent in CD3 - peripheral
blood NK cells, was also expressed. On the other hand, no
Figure 5.
￿
Northern blot analysis of transcripts coding for TCR and
CD3 chains in CD3- cultured thymocyte populations. Total RNA(5 pg)
isolated from a cultured CD3- thymocyte population, aCD3*TCR-a/0
Jurkat T cell line, a CD3*TCR--y/6* Peer T cell line, a Raji B cell line,
andperipheral monocyteswastreated as described in Materials andMethods
andhybridized with thecorrespondingprobes, as indicated. The28S and
18S rRNA subunits used as markers are indicated.
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expression of CD36 transcript could be detected (Fig. 5). Re-
garding the transcripts for TCR genes, a 1.8-kb and a weaker
2.3-kb transcript for TCR-6 gene were detected. Southern
blot analysis revealed that the TCR-6 gene retained the germ-
line configuration (Fig. 6). Moreover, a longer exposure of
the Northern blot for TCR-6 revealed faintbands of 1.3- and
0.8-kb transcripts. Furthermore, these cells expressed a tran-
script of 1.6 kb for TCR-y, and a 1.0-kb (truncated) TCR(3
transcript. In addition, no TCR-a transcript was detectable.
It is noteworthy that the 2.3-kb and 1.3-kb transcripts for
the TCR-6 gene (47) and the 1.6-kb mRNA of the TCR-y
gene had a size similar to the functional mRNAs found in
the TCR-y/b+ Peer cell line.
Discussion
In this study, by applying appropriate culture conditions,
we could obtain an extensive cell proliferation starting from
CD1 -3 -4 -8 - thymocytes. More importantly, the prolifer-
Figure 6.
￿
Southern blot anal-
ysis for TCR-6 gene rearrange-
ments. 5hg ofDNAwasisolated
from theB cell line Raji (lane a)
or a CD3- proliferating thymo-
cyte population (lane b). Restric-
tion patterns afterDNAdigestion
with BamHI indicate that the
TCR 6 chain gene of CD3-
thymocytes is in a germline con-
figuration. Thesizesofthefrag-
ments are indicated.
CD3-TCR-
thymocytes*
None
TNF-a# IFN--yS
Stimuli
PMA
TNF-a
added to
IFN-y
the cytolytic test
PHA
TNF-a IFN-'y
PHA
TNF-a
+ PMA
IFN-y
Thl <10 <1 <10 <1 300 50 1,000 100
Th2 <10 <1 <10 <1 450 80 2,000 300
Clone Thl <10 <1 <10 <1 250 40 1,500 200
Clone Th2 <10 <1 <10 <1 300 70 1,000 100ating thymocytes maintained their original CD3 - TCR -
surface phenotype and yielded cell numbers suitable for fur-
ther phenotypic and functional studies as well as for analysis
of transcripts of CD3/TCR genes. Thus, by the analysis of
both polyclonal or clonal populations, we coulddemonstrate
that CD1 - 3 - 4 - 8- thymocytes acquire effector lymphocyte
functions, including cytolytic activity and lymphokine produc-
tion. In addition, they appear to belong to a T cell differenti-
ation stage characterized by the expression of all the tran-
scripts for CD3 chains, with the exception of CD36 chain.
The minor thymocyte fraction expressing the CD1 - 3 -
4- 8' surface phenotype has been extensively studied in vitro
to analyze its maturation potential and to achieve a better
definition ofthe stages of human T cell development. Along
this line, purified CD1 -3 -4- 8- thymocytes have been shown
to differentiate in culture into CD3+ TCRa/a+ as well as
CD3+ TCR-,y/S+ cells, thus giving rise to the two major
subsets of peripheral T lymphocytes (6-22). In the present
studywe have defined culture conditions that allow prolifer-
ation of CD3' thymocyyes without substantial maturation
into surface CD3+TCR+ cells. Thus, whereas addition of
rIL2 alone or in combination with PHA resulted in the
preferential expansion of CD3+ cells (mostly TCRa/(3+),
the use of low doses of PMA (0.5 ng/ml) plus rIL2 (after
24 h) resulted in an extensive proliferation of CD3- thymo-
cytes. Proliferating cells contained 5-40% CD3+ TCR-
,Y/6 + cells, but no CD3+ TCRa/a+ cells. Further removal
of CD3+ cells yielded highly purified CD3 - cell popula-
tions that proliferated in response to rIL2 and maintained
their CD3 - surface phenotype in culture for up to 8 wk.
That the lack of surface expression of CD3/TCR complex
did not simply reflect a downregulation induced by PMA
is indicated by the following considerations. First, the doses
of PMA reported to induce downregulation of CD3/TCR
molecules were considerably higher (10 ng/ml) (46). More
importantly, CD3+ thymocyyes cultured in the presence of
PMA and rIL2 failed to give rise to CD3- cells, but rather
they were represented by surface CD3+ TCR-a/a + cells.
We can therefore conclude that the doses of PMA used in
our study induced (in conjunction with rIL2) the preferen-
tial proliferation of CD3- thymocyyes. In view of the major
differences detected in the surface phenotype of thymocyte
populations proliferating in response to PMA or PHA, we
analyzed the effect of PHA and 11,2 in CD3 - polyclonal or
clonal thymocyyes that hadbeen pulsed with PMA. Although
not shown, no expression of CD3/TCR could be detected,
thus indicating that PHA and IL2 do not represent stimuli
capable of inducing maturation of these cells.
Surface phenotype analysis of the cultured CD3 - thymo-
cyte populations showed the expression of CD56 antigen,
known to be expressed by peripheral NK cells. Similar to
cultured peripheral NK cells, CD3 - thymocytes displayed
a strong cytolytic activity against both NK-sensitive and NI{
resistant target cells. However, major differences were repre-
sented by the lack of expression of NK cell markers such as
CD16, CD57, and GL183 . In addition, cultured thymocyyes
expressed cytoplasmic CD3 antigen, as detected by several
mAbs known to react with the CD3e chain (44). In no in-
stance under the same experimental conditions did fresh or
cultured CD3- peripheral NK cells express cytoplasmic CD3
antigen (Fig. 4). The lack of surface expression ofNKspecific
triggering molecules was further confirmed by experiments
of re-directed killing using anti-CD16 mAbs. Interestingly,
PHA augmented cytolysis ofP815 target cells, whereas none
of the stimulatory mAbs directed to known triggering sur-
face molecules had any effect . These data suggest that PHA
may activate the lytic machinery of CD3 - thymocytes by
interaction with still undefined triggering surface molecules.
Functional analysis of cultured CD3' thymocyyes re-
vealed, in addition to cytolytic activity, the production of
lymphokines such as IFN-y and TNF-a, but not IL2. In
addition, clonal analysis of CD3- thymocytes indicated that
both functions are expressed by the same cells.
Analysis of the transcripts for CD3 or TCR chains, al-
lowed us to further characterize cultured CD3 - thymocytes
and to distinguish these cells from either CD3+ mature T
lymphocytes or CD3-CD16+ peripheral NK cells. Thus, a
major finding was the presence ofa transcript for CD3,y chain
that is known to be absent in CD3 - CD16+ NK cells (36).
On the other hand, they differed from CD3+ cells because
of the lack of CD36 transcripts. The presence of transcripts
for both TCR-y and -6 chains (displaying a size similar to
the functional mRNA present in TCR-y/6+ cells), together
with the lack ofTCRa transcripts, couldsuggest that these
cells may represent a maturational step towards mature
CD3+ TCR-7/6+ cells. However, this concept is not fur-
ther supported by the finding that TCR-S gene is in agerm-
line configuration (Fig. 6). Our dataprovide further evidence
that genes coding for CDR, y, and 6 chains (although they
are all closely located on chromosome 11) can be expressed
asynchronally in different cell types and/or at different stages
of T cell maturation.
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